Register
Login

Trending Topic

abstract blue eye
8 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

On 28 May 2024, enrolment in phase III clinical trials for sozinibercept in neovascular age-related macular degeneration (nAMD) was completed.1 These trials include two large multicentre, double-masked, randomized controlled trials (RCTs): COAST (OPT-302 with aflibercept in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757636) and ShORe (OPT-302 with ranibizumab in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757610).2,3 These trials represent one of the largest phase […]

Noel Alpins, ESCRS 2020 – Treatment of Astigmatism Using Vector Planning Paradigm

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Oct 15th 2020

It was a pleasure to catch up with Prof. Noel Alpins (Department of Ophthalmology, Melbourne University, Melbourne, Australia), as he discussed the major challenges of refractive surgery in the treatment of astigmatism, and the evidence for the use of Vector Planning in clinical practice.

Questions

  1. What are the major challenges of refractive surgery in the current treatment of astigmatism? (00:05)
  2. Could you give us a brief overview of ocular residual astigmatism (ORA) and the Vector Planning method? (00:52)
  3. What clinical evidence supports the use of this method? (01:56)
  4. Which patients will benefit most from this approach? (04:04)
  5. How can this method become more widely adopted into clinical practice? (05:28)

Speaker Disclosure: Prof. Noel Alpins is CEO of ASSORT Surgical Management Systems.

Support: Interview and filming supported by Touch Medical Media.

Filmed in coverage of ESCRS 2020.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup